FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2116763043> ?p ?o ?g. }

• W2116763043 endingPage "1283" @default.
• W2116763043 startingPage "1276" @default.
• W2116763043 abstract "<h3>Objectives:</h3> The study was conducted with the aim of achieving an improved understanding of the molecular mechanisms of high-dose intravenous immunoglobulin (IVIG) in inflammatory myopathies by investigating the effects on muscle function and immunological molecules in skeletal muscle of polymyositis (PM), dermatomyositis (DM) and inclusion body myositis (IBM) patients. <h3>Methods:</h3> Thirteen treatment-resistant patients, 6 PM, 4 DM, 2 IBM and 1 juvenile DM, were treated with 2 g/kg of IVIG, three times at monthly intervals. Functional Index in Myositis and serum creatinine kinase (CK) levels were determined, and muscle biopsies were performed before treatment and after the third IVIG infusion. Immunological molecules were also studied in biopsies taken 24–48 h after the first infusion. <h3>Results:</h3> Improved muscle function was observed in three patients (1 PM, 1 DM and 1 IBM) and CK levels decreased in five. T cells, macrophages, major histocompatibility complex (MHC) class I antigen on muscle fibres, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) expression and membranolytic attack complex (MAC) deposits on capillaries were present to an equal degree in biopsies before and after IVIG treatment. No correlation between the clinical response and molecular changes was found. <h3>Conclusions:</h3> The clinical effects of high-dose IVIG on muscle function in patients with refractory inflammatory active myositis did not correspond to effects on any of the investigated molecules in our study. T cells, macrophages, phenotypical changes in muscle fibres and endothelial cell activation were still present after treatment. These observations question a role for IVIG as an immune-modulating therapy in patients with inflammatory myopathies." @default.
• W2116763043 created "2016-06-24" @default.
• W2116763043 creator A5006174543 @default.
• W2116763043 creator A5011002229 @default.
• W2116763043 creator A5013827091 @default.
• W2116763043 creator A5023479915 @default.
• W2116763043 creator A5032810028 @default.
• W2116763043 creator A5037527485 @default.
• W2116763043 creator A5065354225 @default.
• W2116763043 date "2007-10-01" @default.
• W2116763043 modified "2023-10-03" @default.
• W2116763043 title "Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies" @default.
• W2116763043 cites W170169453 @default.
• W2116763043 cites W184510336 @default.
• W2116763043 cites W1860657277 @default.
• W2116763043 cites W1897103695 @default.
• W2116763043 cites W1907957486 @default.
• W2116763043 cites W1916794764 @default.
• W2116763043 cites W1970628922 @default.
• W2116763043 cites W1970850123 @default.
• W2116763043 cites W1975756380 @default.
• W2116763043 cites W1976424613 @default.
• W2116763043 cites W1991706567 @default.
• W2116763043 cites W1992958292 @default.
• W2116763043 cites W1993520265 @default.
• W2116763043 cites W1995886968 @default.
• W2116763043 cites W1996838316 @default.
• W2116763043 cites W2008775409 @default.
• W2116763043 cites W2013679387 @default.
• W2116763043 cites W2016490694 @default.
• W2116763043 cites W2021382556 @default.
• W2116763043 cites W2022134162 @default.
• W2116763043 cites W2025267708 @default.
• W2116763043 cites W2048468332 @default.
• W2116763043 cites W2054302835 @default.
• W2116763043 cites W2056651738 @default.
• W2116763043 cites W2063610254 @default.
• W2116763043 cites W2074203661 @default.
• W2116763043 cites W2084861994 @default.
• W2116763043 cites W2151305184 @default.
• W2116763043 cites W2314311014 @default.
• W2116763043 cites W2315610003 @default.
• W2116763043 cites W2329991082 @default.
• W2116763043 cites W2414826436 @default.
• W2116763043 cites W2416870302 @default.
• W2116763043 cites W294572100 @default.
• W2116763043 doi "https://doi.org/10.1136/ard.2006.058644" @default.
• W2116763043 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1994317" @default.
• W2116763043 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17277004" @default.
• W2116763043 hasPublicationYear "2007" @default.
• W2116763043 type Work @default.
• W2116763043 sameAs 2116763043 @default.
• W2116763043 citedByCount "48" @default.
• W2116763043 countsByYear W21167630432012 @default.
• W2116763043 countsByYear W21167630432013 @default.
• W2116763043 countsByYear W21167630432014 @default.
• W2116763043 countsByYear W21167630432015 @default.
• W2116763043 countsByYear W21167630432016 @default.
• W2116763043 countsByYear W21167630432017 @default.
• W2116763043 countsByYear W21167630432018 @default.
• W2116763043 countsByYear W21167630432019 @default.
• W2116763043 countsByYear W21167630432020 @default.
• W2116763043 countsByYear W21167630432021 @default.
• W2116763043 countsByYear W21167630432023 @default.
• W2116763043 crossrefType "journal-article" @default.
• W2116763043 hasAuthorship W2116763043A5006174543 @default.
• W2116763043 hasAuthorship W2116763043A5011002229 @default.
• W2116763043 hasAuthorship W2116763043A5013827091 @default.
• W2116763043 hasAuthorship W2116763043A5023479915 @default.
• W2116763043 hasAuthorship W2116763043A5032810028 @default.
• W2116763043 hasAuthorship W2116763043A5037527485 @default.
• W2116763043 hasAuthorship W2116763043A5065354225 @default.
• W2116763043 hasBestOaLocation W21167630432 @default.
• W2116763043 hasConcept C126322002 @default.
• W2116763043 hasConcept C142724271 @default.
• W2116763043 hasConcept C159654299 @default.
• W2116763043 hasConcept C203014093 @default.
• W2116763043 hasConcept C2776914184 @default.
• W2116763043 hasConcept C2777327098 @default.
• W2116763043 hasConcept C2778552304 @default.
• W2116763043 hasConcept C2778751314 @default.
• W2116763043 hasConcept C2779387793 @default.
• W2116763043 hasConcept C2780181341 @default.
• W2116763043 hasConcept C2781232998 @default.
• W2116763043 hasConcept C71924100 @default.
• W2116763043 hasConcept C90924648 @default.
• W2116763043 hasConceptScore W2116763043C126322002 @default.
• W2116763043 hasConceptScore W2116763043C142724271 @default.
• W2116763043 hasConceptScore W2116763043C159654299 @default.
• W2116763043 hasConceptScore W2116763043C203014093 @default.
• W2116763043 hasConceptScore W2116763043C2776914184 @default.
• W2116763043 hasConceptScore W2116763043C2777327098 @default.
• W2116763043 hasConceptScore W2116763043C2778552304 @default.
• W2116763043 hasConceptScore W2116763043C2778751314 @default.
• W2116763043 hasConceptScore W2116763043C2779387793 @default.
• W2116763043 hasConceptScore W2116763043C2780181341 @default.
• W2116763043 hasConceptScore W2116763043C2781232998 @default.
• W2116763043 hasConceptScore W2116763043C71924100 @default.

• next